Cosentyx is a monoclonal antibody treatment option for several conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and others. Following the initial loading dose, subcutaneous injection of Cosentyx is required every four weeks, but patients can typically be taught to self-administer using the Sensoready pen or prefilled syringe. Nasopharyngitis and an elevated risk of infection are the most frequently reported side effects.
Cosentyx is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondylarthritis, and Enthesitis-related Arthritis.
Humira is a TNF-alpha inhibitor utilized to treat an extensive range of inflammatory conditions, including Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and Ulcerative colitis. However, Humira can suppress the immune system's ability to fight off infections caused by bacteria, fungi, or viruses, potentially increasing the risk of developing certain types of cancer.
Humira is FDA approved for the following indications: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohnâ€™s Disease, Ulcerative Arthritis, Plaque Psoriasis, Hidradenitis Suppurativa, and Uveitis.